New advances in blockade of the renin angiotensin system- The role of renin blockade

Sandra MacRury; L F Clark; G F Rushworth; Stephen J Leslie

doi:10.2174/157340210793611677

New advances in blockade of the renin angiotensin system- The role of renin blockade

Sandra MacRury, L F Clark, G F Rushworth, Stephen J Leslie

Research output: Contribution to journal › Article › peer-review

Abstract

Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

Original language	English
Pages (from-to)	222
Number of pages	231
Journal	Current Hypertension Reviews
Volume	6
Issue number	4
DOIs	https://doi.org/10.2174/157340210793611677
Publication status	Published - 2014

Access to Document

10.2174/157340210793611677

http://benthamscience.com/journal/abstracts.php?journalID=chr&articleID=72883

Sandra MacRury
- sandra.macruryuhi.acuk
- Division of Rural Health and Wellbeing - Professor of Clinical Diabetes, Head of Rural Health and Wellbeing
- Executive Office
Person: Academic Research Active

Cite this

@article{913fb85bdabc42d3ad1740b61b8d1ba2,

title = "New advances in blockade of the renin angiotensin system- The role of renin blockade",

abstract = "Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren. ",

author = "Sandra MacRury and Clark, {L F} and Rushworth, {G F} and Leslie, {Stephen J}",

year = "2014",

doi = "10.2174/157340210793611677",

language = "English",

volume = "6",

pages = "222",

journal = "Current Hypertension Reviews",

issn = "1875-6506",

publisher = "Bentham Science Publishers B.V.",

number = "4",

}

TY - JOUR

T1 - New advances in blockade of the renin angiotensin system- The role of renin blockade

AU - MacRury, Sandra

AU - Clark, L F

AU - Rushworth, G F

AU - Leslie, Stephen J

PY - 2014

Y1 - 2014

N2 - Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

AB - Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

U2 - 10.2174/157340210793611677

DO - 10.2174/157340210793611677

M3 - Article

SN - 1875-6506

VL - 6

SP - 222

JO - Current Hypertension Reviews

JF - Current Hypertension Reviews

IS - 4

ER -

New advances in blockade of the renin angiotensin system- The role of renin blockade

Abstract

Access to Document

Fingerprint

Profiles

Sandra MacRury

Cite this